An extension was required to provide the FDA time to review additional sensitivity analyses of clinical efficacy data from the TRANSCEND trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback